Statistical shortcomings in licensing applications

Statistics in Medicine

Volumn 17, Issue 15-16, 1998, Pages 1663-1673

  Lewis, John A ^a   Facey, Karen M ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CONFERENCE PAPER; DRUG DEVELOPMENT; LICENSING; STATISTICAL ANALYSIS;

EID: 0032529142     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0258(19980815/30)17:15/16<1663::aid-sim969>3.0.co;2-u     Document Type: Conference Paper

References (24)

1. PSI Professional Standards Working Party. PSI Guideline Standard Operating Procedures, Statisticians in the Pharmaceutical Industry, Macclesfield, revised, 1996.
2. Lewis, J. A., Jones, D. R. and Röhmel, J. 'Biostatistical methodology in clinical trials - a European guideline', Statistics in Medicine, 14, 1655-1682 (1995).
3. Food and Drug Administration. Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications, FDA, US Department of Health and Human Services, Rockville, MA, USA, 1988.
4. Ministry of Health and Welfare. Guideline for the Statistical Analysis of Clinical Trials, MHW Pharmaceutical Affairs Bureau, Tokyo, Japan, 1992, (in Japanese).
5. Koopmans, P. P. 'Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market', British Medical Journal, 310, 1305-1306 (1995).
6. Byar, D. P., Schoenfeld, D. A., Green, S. et al. 'Design considerations for AIDS trials', New England Journal of Medicine, 323, 1343-1348 (1990).
7. Commission of the European Communities. Explanatory Note on Expert Reports in the Application Dossier, MCA EuroDirect Publication, Medicines Control Agency, London, U.K., 1996.
8. Smith, A. F. M. 'Mad Cows and ecstasy: chance and choice in an evidence-based society', Journal of the Royal Statistical Society, Series A, 159, 367-383 (1996).
9. Napley, Sir David, 'Lawyers and statisticians', Journal of the Royal Statistical Society, Series A, 145, 422-426 (1982).
10. Cook, R. J. and Farewell, V. T. 'Multiplicity considerations in the design and analysis of clinical trials', Journal of the Royal Statistical Society, Series A, 159, 93-110 (1996).
11. Senn, S. J. 'Covariate imbalance and random allocation in clinical trials', Statistics in Medicine, 8, 467-475 (1989).
12. Jones, D. R. and Lewis, J. A. 'Meta-analysis in the regulation of medicines', Pharamaceutical Medicine, 6, 193-205 (1992).
13. Hedges, L. V. and Olkin, J. Statistical Methods for Meta-analysis, Academic Press, Orlando, 1985.
14. Whitehead, A. and Whitehead, J. 'A general parametric approach to the meta-analysis of randomised clinical trials', Statistics in Medicine, 10, 1665-1677 (1991).
15. Schluchter, M. D. and Forsythe, A. B. 'Post hoc selection of covariates in randomised experiments', Communications in Statistical Theory and Methods, 14, 679-699 (1985).
16. Koch, G. G., Tangen, C. M., Jung, J.-W. and Amara, I. A. 'Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them', Statistics in Medicine, 17, 1863-1892 (1998).
17. Fleming, T. R. and Harrington, D. P. Counting Processes and Survival Analysis, Wiley, New York, 1991.
18. Lindsay, J. K. 'Counts and times to events', Statistics in Medicine, 17, 1745-1751 (1998).
19. Diggle, P. J., Liang, K.-Y. and Zeger, S. L. Analysis of Longitudinal Data, Oxford University Press, Oxford, 1994.
20. Lavange, L. M., Keyes, L. L., Koch, G. G. and Margolis, P. A. 'Application of sample survey methods for modelling ratios to incidence densities', Statistics in Medicine, 13, 343-355 (1994).
21. van Elteren, P. H., 'On the combination of independent two sample tests of Wilcoxon', Bulletin l'Institut de Statistique, 30, 351-361 (1960).
22. Lehmann, E. L. Nonparametrics: Statistical Methods Based on Ranks, Holden-Day, San Francisco, 1975.
23. Jones, B., Jarvis, P., Lewis, J. A. and Ebbutt, A. F. 'Trials to assess equivalence: the importance of rigorous methods', British Medical Journal, 313, 36-39 (1996).
24. Facey, K. M. and Lewis, J. A. 'The management of interim analyses in drug development', Statistics in Medicine, 17, 1801-1809 (1998).